# Application of PPODA-QT for embolization of aneurysms

> **NIH NIH R42** · ANEUVAS TECHNOLOGIES, INC. · 2020 · $718,443

## Abstract

PROJECT SUMMARY/ABSTRACT
 A cerebral aneurysm is an abnormal enlargement or pouch that forms from a
weakened vessel segment in the brain. Often going unnoticed and untreated, an
aneurysm can cause a sudden and catastrophic hemorrhage or stroke. Approximately
15 % of patients die from an aneurysm rupture even before receiving medical attention
and 25 % of patients die despite medical treatment. Patients that survive typically suffer
from various levels of morbidity. Thus, only one in four patients who suffer a ruptured
aneurysm will fully recover. It is estimated that between 3 million and 6 million
Americans have cerebral aneurysms, and approximately 30,000 people in the United
States suffer hemorrhage each year.
 While there have been notable recent advances in providing minimally invasive
access to aneurysms using advanced micro-catheter systems, there is a paucity of
equally high performing embolization materials that can be delivered through these
catheters to effectively treat clinically challenging lesions. The purpose of this venture is
to provide an innovative biomaterial (PPODA-QT) for the endovascular treatment of
aneurysms in order to significantly increase therapeutic effectiveness while minimizing
surgical risks.
 The Phase I proposal developed techniques to test PPODA-QT’s visualization during
injection and its mechanical stability and resistance to particulation and downstream
migration. Successful testing of PPODA-QT leads to this Phase II proposal - to
characterize and optimize PPODA-QT for stability and biocompatibility testing and
submission to the FDA for Investigational Device Exemption (IDE) approval.
Preliminary studies have shown that PPODA-QT can be formulated and delivered to
effectively occlude long-term animal aneurysm models while also promoting a positive
bioactive healing response that may permanently stablize an aneurysm. Our goal is to
begin validation of these preliminary PPODA-QT results by following the comprehensive
procedures laid-out by the FDA to promote safety and efficacy from new liquid embolic
devices. The outcomes of the proposed investigations in this STTR Phase II application,
combined with our previously published research results, will help jump-start the pre-
clinical assessment of PPODA-QT for endovascular embolization of aneurysms.

## Key facts

- **NIH application ID:** 9986040
- **Project number:** 5R42NS097069-03
- **Recipient organization:** ANEUVAS TECHNOLOGIES, INC.
- **Principal Investigator:** Timothy Andrew Becker
- **Activity code:** R42 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $718,443
- **Award type:** 5
- **Project period:** 2017-02-01 → 2022-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9986040

## Citation

> US National Institutes of Health, RePORTER application 9986040, Application of PPODA-QT for embolization of aneurysms (5R42NS097069-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9986040. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*